The Motley Fool

Why I’m Optimistic About GlaxoSmithKline plc’s Future

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is a company that I am a great admirer of, and I know that many readers are, too.

However, one of the major concerns I had about the company was whether it was fully focused on developing its impressive pipeline of drugs and, ultimately, on developing new ones.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

I was also concerned that, with debt levels being rather high, would it be able to generate enough capital with which to compete on the global pharmaceutical stage? This point was especially relevant because of the onerous legal provisions that GlaxoSmithKline must budget for, and which tie-up large amounts of capital that could be used more productively elsewhere.

Both of these fears have now been allayed, with the sale of the Lucozade and Ribena brands to Japanese firm, Suntory, for £1.35 billion.

Not only does the deal allow GlaxoSmithKline to focus on its drug pipeline, the capital will help immeasurably as it seeks to see off competition from peers.

Indeed, although the amount received for the decades-old popular beverages was slightly less than many investors expected, the decision to proceed with the sale is, in my view, a logical one.

I think it’s good news for investors and, as a shareholder, I’m happy with the progress the company is making. In fact, I’m thinking of adding to my shareholding on the back of this news.

As well as the aforementioned news, I’m impressed with the yield offered by GlaxoSmithKline. The company currently pays out 61% of earnings as dividends, so there is scope for this to be increased, although the current yield of 4.4% trumps both inflation and bank savings accounts quite comfortably.

In addition, shares are currently inexpensive on a relative basis. The price-to-earnings (P/E) ratio is 13.9, which compares favourably to the FTSE 100 on 15 and to the wider healthcare industry group on 17.1.

Furthermore, earnings are forecast to grow by 2% this year and 9% next year, showing that there is more to GlaxoSmithKline than just a yield.

So, the recent news on the sale of Lucozade and Ribena, as well as an attractive yield, relatively cheap valuation and impressive growth prospects are making me think about buying more shares in GlaxoSmithKline.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

> Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.